Positron Corp. is a molecular imaging company focused on nuclear cardiology. The company utilizes its proprietary product line to provide unique solutions to the nuclear medicine community ranging from imaging systems to radiopharmaceutical distribution. The molecular imaging market is currently a $5 billion market, with half of the revenue being generated in North America.
Rumors of a lucrative buy-out or partnership occurring in the next week or so continue to swirl around Positron. The chairman of the board, Patrick G. Rooney, has confirmed in an interview with BioMedReports that his company “is currently in discussions with a potential partner in our industry.” BioMedReports is a news portal which covers Wall Street’s biomedical sector.
BioMedReports told its subscribers on Wednesday that the stock price of the 27 year old company could see substantial gains now that Positron had positioned itself to be the leader in nuclear cardiology imaging. The company’s PET scanner, known as the Attrius, has robust cardiac specific imaging software and, more importantly, is the only PET imaging device in the industry. In addition, Positron recently won the 2010 Frost and Sullivan “North American Molecular Imaging Systems New Product Innovation Award.”
In a letter to shareholders last month, Mr. Rooney informed to investors that “Positron has several immediate opportunities with some of the largest companies in the nuclear medicine industry. Any combination of success with these opportunities will have a tremendous positive present and future impact on Positron.” According to today’s exclusive report, Rooney feels confident that the company will thrive financially given that “the cardiac business is five times greater than the oncology business.”
Let us hear your thoughts below: